1. History of coronavirus endoribonuclease {#s0005}
==========================================

We provide a brief outline of the major research findings related to coronavirus (CoV) endoribonucleases (EndoU) in [Table 1](#t0005){ref-type="table"}. In the text below, we describe the experimental approaches that led to these findings and compare the activity of CoV EndoU with reports of other viral and host ribonucleases.Table 1A review of CoV nsp15 research.Table 1**Research topicVirusFindingsReferences**Proteolytic processing of pp1ab and characterizing its cleaved productsHCoV-229EIdentifies a 35 kDa (MHV) and a 41 kDa (229E) proteolytic product of pp1ab. Antibodies characterize p35 and p41 localization to the perinuclear regions.[@bib17][@bib34]MHVBioinformatic analysis of emerging virusesNidovirusesPredicts that nsp15 encodes an endoribonuclease as a nidovirus-wide genetic marker.[@bib37]Biochemical purification and enzymatic analysisSARS-CoVDemonstrates the endoribonuclease activity of nsp15 *in vitro.*[@bib19][@bib6]HCoV-229EMHV[@bib11]IBVTurkey CoVSARS-CoVCharacterizes nsp15 oligomerization, RNA binding, cleavage preference, and restriction factors.[@bib14][@bib7][@bib21]MHVStructural studies of nsp15SARS-CoVStructure studies of nsp15 reveal a unique fold of EndoU.[@bib7][@bib32][@bib43]MHV[@bib20][@bib5]Evaluating the role of nsp15 in virus replicationMHVMutations of the nsp15 active site residues resulted in minimal reduction of viral RNA synthesis and viral titers in fibroblast cell lines.[@bib21]SARS-CoVHCoV-229E[@bib41]Activities of nsp15 detected by overexpression studiesSARS-CoVOverexpression of nsp15 inhibits the IFN response and MAVS-mediated apoptosis; epitope tagged-nsp15 exhibits diffuse pattern of localization.[@bib13][@bib25][@bib10]MHVTGEVIdentifying inhibitors and interacting partnersSARS-CoVSmall molecule inhibitors of Rnase A inhibit EndoU activity and viral replication.[@bib28]MHVSARS-CoVNsp15 interacts with pRb and affects pRb function.[@bib8]MHVEvading host sensorsMHVNsp15 acts as an IFN antagonist and mediates the evasion of dsRNA sensing; nsp15 mutant viruses exhibit severe replication defects in macrophages. MHV nsp15 mutants are highly attenuated in mice.[@bib22]HCoV-229E[@bib12]

1.1. Identifying nsp15 as a component of the CoV replicase polyprotein {#s0010}
----------------------------------------------------------------------

Initial studies focused on identifying the products of the CoV replicase polyprotein, pp1ab (depicted in [Fig. 1](#f0005){ref-type="fig"}A). Heusipp et al. used a murine monoclonal antibody (10G11) that recognizes amino acid residues 6158--6164 of human CoV 229E pp1ab ([@bib17]). They identified a 41-kDa polypeptide in virus-infected cells and found that this polypeptide was a product of the viral 3C-like protease-mediated cleavage of pp1ab. This protein localizes to the perinuclear region, as detected by immunofluorescence assay, similar to other pp1ab-derived polypeptides ([@bib17]). Shi and coworkers obtained similar findings while studying mouse hepatitis virus (MHV) ([@bib34]). They generated a rabbit antiserum against amino acids 6679--6821 of MHV pp1ab and found that this antiserum detected a 35-kDa product in infected cells. They also found that this protein co-localized with *de novo* synthesized viral RNA, and therefore postulated that this viral protein associated with the viral RNA replication/transcription machinery ([@bib34]). Later, the corresponding polypeptides that these antibodies recognized were defined as the 15th cleavage product of pp1ab (called nsp15), counting from the amino-terminus to the carboxyl terminus of pp1ab ([@bib47], [@bib37]).Fig. 1**Coronavirus nsp15 is an endoribonuclease.** (A) Schematic diagram of MHV-A59 genome. Triangles indicate cleavage sites recognized by three viral proteases: papain-like proteases PLP1 (pink) and PLP2 (yellow), and 3C-like protease (3CLpro, green). RdRp, RNA-dependent RNA polymerase; Hel, helicase; ExoN, exoribonuclease; N7-MT, guanosine-N7-methyltransferase; EndoU, endoribonuclease; O-MT, O-methyltransferase; HE, Hemagglutinin-Esterase; E, envelope; M, matrix; N, nucleocapsid. (B) Alignment of the core domains of CoV EndoU and XendoU of *X. laevis*. Putative residues involved in catalysis (\*) or substrate specificity (\#). Abbreviations: MHV, mouse hepatitis virus; OC43, human CoV OC43; HKU1, human CoV HKU1; SARS, severe acute respiratory syndrome CoV; 229E, human CoV 229E; NL63, human CoV NL63; PEDV, porcine epidemic diarrhea virus; IBV, infectious bronchitis virus; PDCoV, porcine delta CoV; XendU, endoribonuclease of *X. laevis.*Fig. 1

1.2. Bioinformatic analysis of nidovirus replicase polyproteins {#s0015}
---------------------------------------------------------------

After the outbreak of Severe Acute Respiratory Syndrome (SARS) in 2002--2003, and once a CoV had been confirmed as the etiological agent of SARS, researchers intensively scrutinized CoV genomic sequences to better understand this novel human pathogen. By comparative genomic characterization of CoV replicases, Snijder *et al.* reported that the C-terminus of nsp15 has high sequence similarity to the *Xenopus laevis* poly(U)-specific endoribonuclease and therefore predicted that nsp15 possesses EndoU activity ([@bib37]). Based on the available sequence information of viruses from the order *Nidovirales* at that time, the EndoU was considered a nidovirus-specific marker (called NendoU) ([Fig. 1](#f0005){ref-type="fig"}B) ([@bib37]). The members of the family *Arteriviridae*, including equine arteritis virus (EAV) and porcine respiratory and reproductive syndrome virus (PRRSV), also have EndoU domains within nsp11. However, it was later discovered that the presence of the EndoU domain is not universal in all nidoviruses. Nam Dinh virus, the first insect nidovirus belonging to the family *Mesoniviridae*, and roniviruses that infect invertebrates, do not encode an EndoU domain ([@bib27], [@bib24]). These findings suggest that the EndoU domain may only serve as a signature for vertebrate nidoviruses, including CoVs and arteriviruses ( [Fig. 2](#f0010){ref-type="fig"}).Fig. 2**Virus-encoded endoribonuclease is a genetic signature of nidoviruses that infect vertebrates.** A phylogenic tree of 32 representative nidoviruses was generated based on a conserved region of RdRp (Sequnces and Genbank Assession numbers are available upon request). Multiple sequence alignment and phylogeny analyses were conducted with the programs MUSCLE and PhyML, respectively (available at <http://www.phylogeny.fr/>). The phylogenic tree was generated using Dendroscope software version 3 with default parameters.Fig. 2

1.3. Biochemical purification and enzymatic analysis of EndoU {#s0020}
-------------------------------------------------------------

Previous reviews have comprehensively summarized the biochemical and structural features of nidovirus ribonucleases ([@bib41], [@bib38]). Here, we highlight the key experiments with respect to nidovirus EndoU and provide recent updates. Studies performed by [@bib19] and [@bib6] first demonstrated the EndoU activity of SARS-CoV nsp15 *in vitro (* [@bib19]; [@bib6]). The wild-type (WT) nsp15 and its mutants with alanine (Ala) substitutions of the putative catalytic residues were expressed in *E. coli*. The recombinant nsp15-WT, but not the mutants, could efficiently cleave single-stranded (ss) and double-stranded (ds) RNAs. In contrast, neither ssDNA nor dsDNA molecules could be processed by nsp15, demonstrating its predicted ribonuclease---as opposed to deoxyribonuclease---activity. Blocking either the 5′ or the 3′ terminus of the RNA substrates by covalent modifications with fluorescein or puromycin, respectively, had no effect on the RNA cleavage ([@bib6]), confirming that nsp15 is an endo- rather than an exoribonuclease. Similar EndoU activity was detected in other CoV nsp15s, including human CoV 229E, MHV, infectious bronchitis virus (IBV), and turkey CoV ([@bib19], [@bib6], [@bib11]), and in the nsp11s of arteriviruses EAV and PRRSV ([@bib26]).

Hexamerization of nsp15 is critical for its EndoU activity. Guarino and coworkers found that CoV nsp15 could be present in solution as either monomers or hexamers in a protein concentration-dependent manner. The hexamer is the fully active form of EndoU that binds RNA and executes optimal EndoU activity ([@bib14]). The residues in the N-terminal domain of nsp15 are critical for hexamer formation ([@bib14]). In addition, nsp15 requires divalent metal ions as a co-factor for RNA cleavage and prefers Mn^2+^ over Mg^2+^ or other divalent cations ([@bib19], [@bib6]). Addition of Mn^2+^ significantly affects the protein conformation, enhances RNA binding, and increases EndoU activity ([@bib19]; [@bib6]). In contrast to CoV nsp15, arterivirus nsp11 forms dimers in solution and does not require divalent cations as a cofactor for activity *in vitro* ([@bib26], [@bib36]). Instead, a concentration of Mn^2+^ that greatly stimulated the activity of CoV nsp15 inhibited the EndoU activity of EAV and PRRSV nsp11s.

CoV EndoU was revealed biochemically to hydrolyze the 3′ end of pyrimidines, with a preference for uridylates, and release products with 2′, 3′-cyclic phosphate and 5′-hydroxyl ends ([@bib19], [@bib6]). This finding seems to implicate a broad range of targets; however, the EndoU activity of CoV nsp15 can be affected by secondary structure and modification of the RNA substrate. Bhardwaj et al. found that nsp15 preferentially cleaved unpaired uridylates in hairpin-structured RNAs and that the neighboring nucleotides of targeted sites also influenced hydrolysis ([@bib7]). On the other hand, Ivanov et al. found that 2′-O-ribose methyl groups present on the substrate RNA blocked EndoU-mediated cleavage ([@bib19]). These data suggest that multiple factors might limit the range of EndoU targets. This is reasonable because the EndoU activity of nsp15 is likely to be tightly regulated during infection in cells to avoid unwanted cleavage on viral and/or cellular targets. For example, CoV nsp16 is a 2′-O-ribose methyltransferase, whose function could theoretically block the EndoU-mediated cleavage of viral RNAs. Similar to CoV nsp15, arterivirus nsp11 also prefers 3′ of uridylates for cleavage and yields products with 2′, 3′-cyclic phosphate ends ([@bib26]). Further studies are needed to address whether the EndoU activity of arterivirus nsp11 is restricted by RNA modifications or secondary structures.

1.4. Structural studies reveal unique features of CoV EndoU {#s0025}
-----------------------------------------------------------

Guarino and coworkers visualized single particles of SARS-CoV nsp15 using electron microscopy ([@bib14]) and the same group later reported an 8.3 Å structure of nsp15 by cryoelectron microscopy ([@bib7]). They reported that the nsp15 hexamer comprises a dimer of trimers and proposed that the RNA substrate binds to the inter-trimer interface. X-ray crystal structures of SARS-CoV and MHV nsp15s were first solved by Ricagno *et al.* and Xu et al., respectively ([@bib32]; [@bib43]). These high-resolution structures define CoV nsp15 as a separate EndoU family with unique folds that differ from cellular endoribonucleases ( [Fig. 3](#f0015){ref-type="fig"}A). The monomer of SARS-CoV nsp15 consists of three domains: a small N-terminal domain (NTD) (residues 1--62, cyan), a middle domain (residues 63--191, magenta), and a large C-terminal domain (CTD) (residues192--345, green). The EndoU is located in the CTD. The monomeric structure of MHV nsp15 can be superimposed onto that of SARS-CoV nsp15, except for a flexible loop structure in the middle domain of MHV nsp15 ([Fig. 3](#f0015){ref-type="fig"}B). This flexible loop is encoded by a viral RNA packaging signal sequence, which is present in MHV nsp15 but not in SARS-CoV nsp15 ([@bib23]). These structural studies demonstrated that the presence of the flexible loop did not alter the overall folding of MHV nsp15 relative to SARS-CoV nsp15. In addition, through these and other structural studies ([@bib32], [@bib43], [@bib20], [@bib5]), the nsp15 hexamer was again confirmed to be a dimer of trimers. As shown in [Fig. 3](#f0015){ref-type="fig"}C, three monomers form a trimer and two trimers interact head-to-head to form a hexamer. The NTDs line up in the center of the hexamer, while the CTDs face outward. This architecture allows the nsp15 hexamer to possess six active sites. The extensive contact between subunits through the NTD and middle domain is critical for hexamerization. The crystal structure of arterivirus nsp11 was also recently reported ([@bib36], [@bib44]). These structural studies revealed that the monomer of nsp11 contains only two domains: NTD and CTD (no middle domain). The monomeric structures of CoV nsp15 and arterivirus nsp11 could not be superimposed except in the CTD (catalytic domain). Distinct from the hexameric structure of CoV nsp15, nsp11 monomers assembled into an asymmetric dimer ([@bib36]).Fig. 3**Structural features of nsp15.** (A) The three domains of the SARS-CoV nsp15 monomer (Protein Data Bank code: 2H85): N-terminal domain (cyan), middle domain (magenta), and C-terminal domain (green). Catalytic residues are shown in red. (B) Structural comparison of SARS-CoV nsp15 (cyan) and MHV nsp15 (magenta, 2GTH). A flexible loop encoded by the packaging signal sequence of MHV nsp15 is circled. (C) Hexamer of SARS-CoV nsp15 (2RHB). The catalytic residues of one monomer are highlighted in magenta (left); the catalytic pockets of a hexamer are indicated by arrows (right).Fig. 3

1.5. EndoU activity can be inhibited by small molecules {#s0030}
-------------------------------------------------------

Since the crystallographic studies of CoV nsp15 revealed that the active site of EndoU is structurally similar to that of RNase A, researchers evaluated small molecule inhibitors of RNase A for their ability to inhibit nsp15 activity. Ortiz-Alcantara et al. tested several commercially available RNase A inhibitors (Benzopurpurin B, Congo red, and others) and reported that their 50% inhibitory concentration (IC~50~) values for inhibiting the EndoU activity of SARS-CoV nsp15 ranged from 0.2 μM to 40 μM. Benzopurpurin B was shown to have a broad-spectrum activity and could inhibit nsp15 orthologs from MHV and IBV with IC~50~ values of 0.4 μM and 0.2 μM, respectively ([@bib28]). These RNase A inhibitors had variable effects on CoV replication in cell cultures. In plaque formation assays, treatment with Congo red resulted in 27-fold and 4-fold reductions in MHV and SARS-CoV titers, respectively, while Benzopurpurin B led to marginal inhibition of both CoVs ([@bib28]). Although the impact of these RNase A inhibitors on CoV replication requires more comprehensive investigation, these early results suggest that the similarity between nsp15/EndoU and RNase A may provide a basis for exploiting small molecule inhibitors to modulate viral EndoU activity.

1.6. Evaluating the role of nsp15 in coronavirus replication {#s0035}
------------------------------------------------------------

Due to its unique enzymatic activity and co-localization with the replicating viral RNA, nsp15/EndoU was initially thought to play an important role in virus replication. However, MHV encoding catalytic-defective EndoU exhibited only a subtle defect in RNA synthesis and a slight reduction in viral titers (\~ 1 log) compared to WT virus when evaluated in fibroblasts ([@bib21]). Similar results were obtained for SARS-CoV and HCoV-229E nsp15 mutants generated using either reverse genetics or replicon systems ([@bib41]). These data indicate that the EndoU activity of nsp15 is not essential for CoV replication, as was initially proposed ([@bib37], [@bib19], [@bib6]). Intriguingly, nsp15 may indirectly affect virus replication through other mechanisms. Ivanov *et al.* demonstrated that when the conserved aspartic acid (Asp)-298 of HCoV-229E nsp15 was replaced with an Ala, its EndoU activity was eliminated, viral RNA synthesis was completely abolished, and no viable virus was recovered ([@bib19]). Similar phenotypes were observed for an MHV nsp15 mutant with an Ala substitution of Asp-324 (equivalent to Asp-298 of HCoV-229E) ([@bib21]). It is unclear how the Asp residues affect viral RNA synthesis. Kang *et al.* predicted that Asp-324 is critical for an ionic-bond network and observed that the Ala substitution resulted in an insoluble protein when MHV nsp15 was expressed in *E. coli (* [@bib21] *)*. These data suggest that the Ala substitution may prevent the nsp15 protein from folding correctly. Since the proteins adjacent to nsp15 are critical replicative components, any protein-folding issue with nsp15 may have an effect on the proteolytic processing of the neighboring components, thereby leading to a nonviable phenotype. Overall, current evidence indicates that the EndoU activity of CoV nsp15 is dispensable for viral RNA synthesis and virus replication in cell culture. Further work is required to address any non-EndoU-mediated role of nsp15 protein in virus replication.

Mutagenesis of arterivirus nsp11 revealed pleiotropic effects of EndoU on the viral life cycle ([@bib29], [@bib39]). Similar to CoV nsp15, mutations in the Asp-3014 and Asp-3038 residues (corresponding to MHV nsp15 Asp-324 and Asp-351, respectively) in EAV nsp11 resulted in a nonviable phenotype. Compared with the mild effect of mutating the catalytic histidine (His) residues (His262Ala and His277Ala) of MHV nsp15, EAV infectious clones with catalytic residue mutations (His2963Ala/Gln and His2978Ala/Gln) exhibited smaller plaque sizes, reduced RNA synthesis, and dramatic titer reductions up to 5 log units. Other substitutions at conserved, non-catalytic residues of EAV nsp11 resulted in an intermediate phenotype: intermediate plaque sizes and \~1--2 log reduction in titers. Similar results were obtained with the PRRSV nsp11 mutant viruses ([@bib39]). These data indicate that arterivirus nsp11 may be involved in viral RNA synthesis. However, similar to the Asp324Ala mutation of MHV nsp15, both Asp3014Ala and Asp3038Ala mutations in EAV nsp11 rendered the protein insoluble, again raising the question of whether or not these mutations influence viral RNA synthesis through interfering with proteolytic processing of the ORF1b polyprotein. The absence of an EndoU domain in insect nidoviruses and invertebrate roniviruses further indicates that EndoU activity is not required for the unique RNA synthesis strategy of nidoviruses ([@bib27], [@bib24]).

The aforementioned studies highlight the extensive efforts of the field to investigate the characteristics of nsp15/EndoU and its role in virus life cycle. The EndoU activity of CoV nsp15 was found to play a non-essential role in viral RNA synthesis and replication in immortalized fibroblast cells. Recent work with different cell types and *in vivo* experiments revealed a novel function of nsp15/EndoU in virus replication and pathogenesis and provided a new direction of study with respect to this "old" protein.

1.7. Ectopic expression of nsp15 reveals antagonism of reporters {#s0040}
----------------------------------------------------------------

CoV nsp15 was first suggested to possess interferon (IFN) antagonism capabilities through ectopic expression experiments. Frieman *et al.* used an alphavirus replication-defective vector (VRP) to screen SARS-CoV proteins that suppress VRP-induced IFN responses. One of the identified IFN antagonists of SARS-CoV was nsp15 ([@bib13]). Later, arterivirus nsp11 was also identified as an IFN antagonist and its EndoU activity was found to mediate inhibition of IFN-beta induction ([@bib4], [@bib35]). Several other studies also reported that CoV nsp15 and arterivirus nsp11 inhibit cellular innate responses in ectopic expression experiments ([@bib25], [@bib42]). These data seem to indicate that these two proteins function as IFN antagonists; however, the EndoU activity of overexpressed nsp15/nsp11 may unexpectedly affect the activities of the reporters used in these assays. We found that transfected MHV nsp15 reduced the signal of both IFN-reporter firefly luciferase and the internal control renilla luciferase (Hackbart M, Deng X, and Baker S, unpublished data). A similar result was obtained with the overexpressed PRRSV nsp11 ([@bib36]). These observations imply that nsp15/nsp11 may execute non-specific cleavage when ectopically expressed. Since CoV nsp15 is part of the viral replicase/transcriptase complex (RTC), it is reasonable to predict that its EndoU activity is tightly regulated during viral infection to avoid unwanted cleavage. In line with this prediction, we and others reported a specific, punctate, perinuclear localization of CoV nsp15 during viral infection ([@bib1], [@bib12], [@bib17], [@bib34]), while ectopically expressed nsp15 was distributed throughout the cytoplasm ([@bib10]). Hence, we advise caution when interpreting the results of overexpression studies, as the nature of the EndoU activity was only revealed after studying nsp15/nsp11 in the context of viral infection.

1.8. EndoU is important for evading host sensors of dsRNA {#s0045}
---------------------------------------------------------

It was first discovered that the EndoU activity of nsp15 mediates the evasion of host recognition of viral dsRNA by infecting primary macrophages with EndoU-deficient CoVs ([@bib12], [@bib22]). Infection with MHV EndoU-deficient mutants stimulated mouse bone-marrow derived macrophages (BMDMs) to produce a remarkably high level of type I IFNs during the early phase of infection compared to WT infection. This IFN response is MDA5-dependent, as both the IFN mRNA and protein levels were not elevated in MDA5-deficient BMDMs. Moreover, the replication of EndoU-deficient CoVs was severely impaired in primary macrophages. Interestingly, the IFN-induced antiviral response is not the only player responsible for this replication defect, as the titers of the EndoU-deficient CoVs were not completely restored in BMDMs that lack critical genes (*e.g.* MDA5, MAVS, and IRF3/5/7) involved in the IFN response ([@bib12], [@bib22]). These data suggest that other antiviral pathways may also contribute to the observed replication defect. In support of this, it was found that the infection of EndoU-deficient CoVs also activate the PKR and the OAS-RNase L pathways ([@bib12], [@bib22]), which both execute potent antiviral functions, discussed further below. Indeed, the replication of EndoU-deficient CoVs could be partially restored in PKR/RNase L-double knockout cells ([@bib22]). Replication was only fully restored in type I IFN receptor-knockout macrophages, as these cells not only have a defect in IFN signaling but also express very low basal levels of PKR and OAS relative to WT cells ([@bib12], [@bib9]). Taken together, these studies using live viruses in primary cells effectively illustrated the IFN antagonistic properties of CoV EndoU.

As mentioned above, infection with EndoU-deficient CoVs also activates the PKR and OAS-RNase L pathways in macrophages ([@bib12], [@bib22]). PKR is a dsRNA-activated protein kinase and serves as a dsRNA sensor. Activated PKR phosphorylates eukaryotic initiation factor 2α (eIF2α), resulting in inhibition of host and viral mRNA translation. Thus, PKR-mediated translation shutoff plays an important role in the host antiviral defense ([@bib2]). The EndoU-deficient CoV-infected macrophages exhibited increased levels of phosphorylated eIF2α and decreased levels of translation ([@bib12], [@bib22]), indicating that PKR was activated during infection. Another piece of evidence of PKR activation was that EndoU-deficient CoVs induced rapid apoptotic cell death in infected-macrophages ([@bib12]). It has been shown that PKR-mediated translation shutoff leads to apoptosis in macrophages ([@bib18]). When the EndoU-deficient CoV-infected macrophages were treated with a PKR-specific inhibitor (C16), the level of apoptosis was significantly reduced ([@bib12]). This result further supports the hypothesis that EndoU-deficient CoVs activate PKR. Interestingly, loss of PKR expression or inhibition of its activity only partially restored the replication of EndoU-deficient CoVs in macrophages ([@bib22]). Moreover, treatment with the PKR inhibitor did not affect IFN induction or RNase L-mediated ribosomal RNA degradation in the EndoU-deficient CoV infected-macrophages (Deng *et al.*, unpublished data). These results imply that the infection of EndoU-deficient CoV activates multiple host dsRNA sensors independently, including MDA5, PKR, and OAS.

OAS is a protein family of 2′, 5′-oligoadenylate (2--5A) synthetases. Upon activation, OAS can synthesize 2--5A, which binds to and activates RNase L. RNase L is a host ribonuclease that executes global degradation of host and viral RNAs. Thus, OAS and RNase L constitute a potent host antiviral system. Macrophages infected by the EndoU-deficient CoVs exhibited an early, RNase L-mediated degradation of ribosomal RNA, demonstrating that the OAS-RNase L system was activated ([@bib12], [@bib22]). Lack of MDA5 expression or treatment with the PKR inhibitor did not affect virus-induced RNA degradation ([@bib12], [@bib22]), suggesting that the nsp15-mediated blockage of OAS-RNase L activation is independent of the MDA5-IFN and PKR pathways. Loss of RNase L expression does not restore the replication of EndoU-deficient CoVs in macrophages. Taken together, these results suggest again that multiple antiviral pathways, including MDA5-IFN, PKR, and the OAS-RNase L system, were activated during infection with EndoU-deficient CoVs. The antiviral defense executed by these pathways contribute together to the replication defect of EndoU-deficient CoVs in macrophages. Interestingly, some CoVs encode a 2′, 5′-phosphodiesterase (PDE) (*e.g.* MERS-CoV orf4b and MHV ns2) ([@bib40], [@bib45]). This CoV PDE also prevents RNase L-mediated RNA degradation through digesting the 2--5A produced by OAS. Thus, the presence of two antagonists of the OAS-RNase L system in some CoV genomes represents a functional redundancy or tissue-specific roles for these antagonists. In fact, not all CoVs encode a PDE, and it has been reported that loss of the PDE activity mitigated MHV pathogenicity in the mouse liver but not in the brain, suggesting a liver-specific effect of CoV PDE activity *in vivo* ([@bib33]; [@bib46]).

1.9. Lack of phenotype of EndoU-deficient CoVs in fibroblast cell lines {#s0050}
-----------------------------------------------------------------------

Several EndoU-deficient CoVs have been evaluated in fibroblast cell lines and no marked phenotypes were obtained (mild reduction of viral RNA synthesis and replication) (discussed above). We speculate that the activation of an IFN response and apoptosis in macrophages is due to high levels of basal expression of host sensors, such as MDA5, PKR, and OAS ([@bib12], [@bib9]). Indeed, when the expression of OAS was induced by pre-treatment with IFN, the immortalized fibroblast cells also exhibited RNA degradation upon infection with EndoU-deficient CoV ([@bib22]). In line with this, without the stimulation of IFN, constitutively expressed OAS and PKR in the MDA5-deficient macrophages is capable of sensing the EndoU-deficient CoV infection and implementing antiviral processes ([@bib12]). Although the production of IFN is dispensable for the activation of the OAS-RNase L system and PKR, type I IFN receptors or a direct signal is required for maintaining the high basal expression of these IFN-inducible genes ([@bib12], [@bib9]). This is biologically relevant because macrophages and other myeloid cells are quick responders to early virus infection, responding even before IFN is highly induced. It is unclear whether other cell types, such as epithelial cells, behave similar to macrophages, but at least mouse embryonic fibroblasts have been shown to display the nsp15/EndoU-mediated effects ([@bib22]).

1.10. MHV EndoU-deficient mutants are highly attenuated in mice {#s0055}
---------------------------------------------------------------

Due to robust activation of antiviral responses, MHV EndoU-deficient mutants also exhibited a marked attenuation *in vivo* relative to MHV-WT. Depending on the inoculation route, MHV infection can result in hepatitis or encephalitis in C57/BL6 mice. Strikingly, regardless of which infection route (intraperitoneal or intracranial injection) was used, we found that MHV EndoU-deficient mutants were highly attenuated ([@bib12]). When mice were inoculated intraperitoneally using a high dose of the mutant virus, there was no detectable viral titer in the liver or spleen at day 3 post-infection and only a minimal detection of viral mRNA in mesenteric lymph nodes at day 1 post-infection. When a sensitive encephalitis model was used, mice infected with MHV EndoU-deficient mutants exhibited only a transient loss of body weight and recovered completely. This significant attenuation is attributed to the loss of EndoU-mediated evasion of host antiviral defenses. We found that EndoU-deficient mutants maintained WT-level virulence in type I IFN receptor knockout (IFNAR^-/-^) mice ([@bib12]). Similar results obtained by Kindler *et al.* showed that the mutant virus was only detected in the organs from IFNAR^-/-^ mice but not wild-type or other gene-deficient (MDA5^-/-^, TLR7^-/-^, and MDA5^-/-^/TLR7^-/-^) mice at day 2 post-infection ([@bib22]). Interestingly, even though MHV EndoU-deficient mutants were highly attenuated and exhibited limited replication *in vivo*, the pre-infected mice were protected from subsequent lethal challenges of wild-type MHV in both disease models ([@bib12]). These results demonstrate that nsp15 plays an important role in virus pathogenesis and illustrate the potential use of EndoU-deficient CoVs as vaccine candidates.

1.11. How does nsp15 mediate the evasion of host sensors? {#s0060}
---------------------------------------------------------

As an EndoU, it is plausible that nsp15 may degrade viral dsRNA to prevent host recognition. Previous studies of pestivirus envelope glycoprotein (E^rns^) and Lassa virus nucleoprotein linked viral ribonuclease activity to type I IFN antagonism through degrading viral dsRNA ([@bib30], [@bib31], [@bib16]), although no direct evidence for this linkage has been obtained. For CoV nsp15, Kindler et al. detected an increased level of dsRNA in EndoU mutant-infected cells by flow cytometry using a dsRNA-specific monoclonal antibody (mAb) ([@bib22]). This mAb recognizes dsRNA molecules longer than 40 bp in length, regardless of the sequence, meaning that a long dsRNA could potentially bind multiple mAb molecules. To saturate the mAb-dsRNA binding, we tested serial concentrations of antibody but did not detect any significant change of dsRNA levels by either flow cytometry or immunofluorescence analysis ([@bib12]). The discrepancy between these two studies may be ascribed to the experimental settings in respective experiments. However, it is also possible that the methods used in these studies may not be sensitive enough to detect changes in dsRNA levels if the WT-nsp15 produces dsRNA cleavage products that are \>40 bp, such that the uncleaved and cleaved dsRNAs are indistinguishable for binding by the anti-dsRNA antibody. Importantly, it has been demonstrated that the EndoU activity of CoV nsp15 is influenced by secondary structures and modifications of dsRNA ([@bib19], [@bib7]). Because these factors may limit the number of cleavage events and/or the targets of EndoU, nsp15-mediated cleavage may produce few overall cleavage products that are \<40 bp. Consequently, nsp15-mediated cleavage may not reduce the level of total dsRNA in the cell, but rather may hydrolyze long dsRNAs into shorter cleavage products that are sufficiently short to evade recognition by host sensors (*e.g.* MDA5) but not by the anti-dsRNA antibody.

It has been documented that CoV dsRNAs form cytoplasmic aggregated foci during replicating in cells ([@bib3], [@bib15]). These dsRNA foci co-localize with the viral RTCs early during infection. Interestingly, we noted that during the early stages of infection, dsRNA foci were not co-localized with the RTCs in the EndoU-deficient CoV-infected cells. This decrease in co-localization relative to WT infection resulted in a dispersed pattern of dsRNA foci, such that some dsRNAs did not appear to associate with the RTCs. It is not known whether these "free" dsRNAs trigger host sensors, but this dispersed distribution of dsRNA does notably coincide with early activation of the IFN response and other dsRNA sensors (*e.g.* PKR and OAS). Overall, additional studies with new methods are needed to characterize the intracellular localizations and the fates of dsRNA in CoV-infected cells.

2. Significance and perspectives {#s0065}
================================

The detailed strategy used by CoV EndoU to evade host recognition remains enigmatic. More studies are needed to address several key questions: (i) What is the natural target of EndoU? (ii) How does the EndoU activity of nsp15 alter the fate of dsRNA? (iii) How is this EndoU activity regulated to avoid unwanted cleavage events? (iv) Do any interaction partners (viral or cellular) of nsp15 participate in regulating its EndoU activity ([@bib1], [@bib8])? Answers to these questions will be essential for understanding the mechanism of the EndoU-mediated evasion of host dsRNA sensors. Additionally, it is possible that EndoU serves as a conserved antagonist in vertebrate nidoviruses. A similar phenotype has been observed in human blood-derived macrophages infected with the HCoV-229E nsp15 mutant virus ([@bib22]), which is a representative alphacoronavirus. Whether arterivirus nsp11 also functions as an IFN antagonist during infection is still unknown. One obstacle to studying arterivirus nsp11 mutants in cell culture is that mutations of catalytic residues have been reported to severely affect viral replication even in IFN-deficient cells ([@bib29], [@bib39]). Nonetheless, given the striking roles of CoV EndoU in macrophages and *in vivo*, it will be important to understand the underlying mechanism of EndoU-mediated evasion of host antiviral defenses in order to advance an ultimate goal of exploiting this enzyme as a target for therapeutics and vaccine design against existing and emerging pathogenic CoVs.
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